Physician profile
John Chang
NPI 1073516027
$4,594.76
in general payments reported to CMS, 2019-2025
24 companies · $981 in 2025
The $981 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $211 · 2021: $242 · 2022: $474 · 2023: $837 · 2024: $1,186 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,053.21 | 2019-2025 | Tryptyr, Clareon Panoptix Pro, Rocklatan |
| Glaukos Corporation | $845.25 | 2019-2024 | Idose |
| Sun Pharmaceutical Industries INC. | $591.82 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $366.72 | 2023-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Abbvie INC. | $328.75 | 2022-2023 | Durysta, Lumigan, Alphagan P |
| Rxsight INC | $288.17 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $237.63 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $139.74 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Ocular Therapeutix, INC. | $117.27 | 2023-2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $114.32 | 2019-2023 | Tecnis Iol |
| Allergan, INC. | $90.06 | 2019-2022 | |
| Oyster Point Pharma, INC. | $67.03 | 2024-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $44.92 | 2022-2024 | Rayone Spheric, Omidria, Rayone Emv |
| Kala Pharmaceuticals, INC. | $37.57 | 2019 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $33.44 | 2019 | |
| Dompe US, INC. | $33.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.44 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.10 | 2019-2020 | |
| Harrow Eye, LLC | $28.59 | 2025 | Vevye |
| Shire North American Group INC | $22.61 | 2019 | |
| Aerie Pharmaceuticals, INC. | $21.18 | 2019 | |
| Thea Pharma INC. | $19.09 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $16.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.